NCT07277179

Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing Spondylitis

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing Spondylitis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 113 (actual)
• Sponsor: SPH-BIOCAD (HK) Limited · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to To evaluate the efficacy of subcutaneous (SC) Netakimab in adult Chinese patients with Active Ankylosing Spondylitis. Researchers will compare Netakimab to placebo to see if Netakimab works to treat Ankylosing Spondylitis.

Conditions

• Ankylosing Spondylitis

Interventions

Type	Name	Description
DRUG	Netakimab	Netakimab administered subcutaneously
DRUG	Placebo	Placebo administered subcutaneously

Timeline

• Start date: 2023-03-20
• Primary completion: 2024-07-05
• Completion: 2025-05-16
• First posted: 2025-12-11
• Last updated: 2025-12-11

Locations

1 site across 1 country: China